Uncategorized
Phase 3 study demonstrates efficacy of new dry eye treatment
AMSTERDAM — Liftegrast, a new integrin-antagonist molecule, demonstrated to be well tolerated and effective in relieving dry eye symptoms in a phase 3 study. “Chronic inflammation is widely accepted as responsible for the cycle that causes many types of dry eye disease. Liftegrast blocks T-cell activation, proliferation, adhesion and migration, a key step in the chronic dry eye inflammatory cycle,” John Sheppard, MD, said at the European Society of Cataract and Refractive Surgeons meeting.